Ligand Pharmaceuticals (LGNDZ) Enterprise Value (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Enterprise Value for 16 consecutive years, with -$733.5 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 186.35% to -$733.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$733.5 million through Dec 2025, down 186.35% year-over-year, with the annual reading at -$733.5 million for FY2025, 186.35% down from the prior year.
- Enterprise Value hit -$733.5 million in Q4 2025 for Ligand Pharmaceuticals, down from -$664.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$38.3 million in Q2 2024 to a low of -$733.5 million in Q4 2025.
- Historically, Enterprise Value has averaged -$269.2 million across 5 years, with a median of -$232.0 million in 2023.
- Biggest five-year swings in Enterprise Value: skyrocketed 82.52% in 2024 and later plummeted 788.97% in 2025.
- Year by year, Enterprise Value stood at -$341.1 million in 2021, then soared by 37.89% to -$211.9 million in 2022, then rose by 19.62% to -$170.3 million in 2023, then plummeted by 50.41% to -$256.2 million in 2024, then tumbled by 186.35% to -$733.5 million in 2025.
- Business Quant data shows Enterprise Value for LGNDZ at -$733.5 million in Q4 2025, -$664.5 million in Q3 2025, and -$245.0 million in Q2 2025.